Original language | English |
---|---|
Pages (from-to) | 535-536 |
Number of pages | 2 |
Journal | Obstetrical and Gynecological Survey |
Volume | 76 |
Issue number | 9 |
DOIs |
|
State | Published - 1 Sep 2021 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
The SOLO2/ENGOT-Ov21 Investigators
- Hospital Quirónsalud Valencia
- Grupo Español de Investigación en Cáncer de Ovario (GEICO)
- Centre Georges-François Leclerc
- Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
- University College London
- Institute of Cancer Research
- University of Sydney
- Massachusetts General Hospital
- Princess Margaret Hospital
- Israeli Society of Surgical Oncology
- Pomeranian Medical University in Szczecin
- Read-Gene SA
- IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
- Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies
- University of New South Wales
- IRCCS Istituto Oncologico Veneto - Padova
- IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica
- Hannover Medical School
- German Society of Gynecological Oncology
- National Cancer Center Japan
- Netherlands Cancer Institute
- Dutch Gynecological Oncology Group
- St Petersburg City Clinical Oncology Dispensary
- Yonsei University
- Korean Gynecologic Oncology Group
- Universidade de São Paulo
- AstraZeneca
- KU Leuven
- Belgium and Luxembourg Gynaecological Oncology Group (BGOG)
- Association de Recherche Contre les Cancers dont Gynécologiques-ARCAGY
Research output: Contribution to journal › Comment/debate
3
Scopus
citations